Coenzyme I — Competitive Intelligence Brief

Coenzyme I (NADIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin C [EPC]. Area: Metabolic.

marketed Vitamin C [EPC] Metabolic Small molecule

Target snapshot

Coenzyme I (NADIDE).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Coenzyme I TARGET	NADIDE		marketed	Vitamin C [EPC]
Infuvite Adult	alpha-tocopherol acetate	Novartis	marketed	Vitamin C [EPC]		2000-01-01
Glucoferron	FERROUS GLUCONATE	Sanofi	marketed	Vitamin C [EPC]		1999-01-01
Pyridoxine Hydrochloride	PYRIDOXINE	Pfizer	marketed	Vitamin C [EPC]	Cystathionine beta-synthase	1993-01-01
Vitamin B5	CALCIUM PANTOTHENATE	Pfizer	marketed	Vitamin C [EPC]		1993-01-01
Renacidin	MAGNESIUM CARBONATE	United Guardian	marketed	Vitamin C [EPC]		1990-01-01
Iron Fumarate	FERROUS FUMARATE	Pfizer	marketed	Vitamin C [EPC]		1986-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin C [EPC] class)

1. · 16 drugs in this class
2. Pfizer · 5 drugs in this class
3. Energique, Inc. · 2 drugs in this class
4. Exela Pharma · 1 drug in this class
5. Faculdade de Medicina do ABC · 1 drug in this class
6. Glaukos · 1 drug in this class
7. Hippocration General Hospital · 1 drug in this class
8. Jun Gong, MD · 1 drug in this class
9. MEDPOINTE PHARM HLC · 1 drug in this class
10. Novartis · 1 drug in this class